PPN12: DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN MIGRAINEURS WITH AND WITHOUT PROPHYLACTIC MEDICATION USE  by Girts, TK et al.
Abstracts 157
PPN10
SURVIVAL AND NURSING HOME FREE 
SURVIVAL (NHFS) OF AD PATIENTS
Wu EQ, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To model survival and NHFS of Alzheimer
Disease (AD) patients. To justify the Mini-Mental Status
Examination (MMSE) score as an important predictor of
patient survival and nursing home utilization. METH-
ODS: Survival models were applied to analyze the Mini-
mum Uniform Data Set (MUDS), developed and main-
tained by Alzheimer Research Centers of California
(ARCC). The study sample included 3150 AD patients,
who enrolled in ARCC between Oct. 1992 and Jan.
1999. Cox regression models with and without time-
dependent covariates were used in the analysis. Results
were adjusted by comorbidities. RESULTS: The MMSE
score was shown to be a strong predictor of both AD pa-
tients’ survival and NHFS. One-unit increase of MMSE
score (on a 30-point scale) corresponds to a 5.5% hazard
reduction. That is to say, if a patient’s 5-year survival
probability is 0.500, with his MMSE score increased by
one unit, the probability will be increased to 0.520. One
unit increase of MMSE also corresponds to 6.4% hazard
reduction in future nursing home utilization, which
means a NHFS probability of 0.500 will be increased to
0.523. Female, black, and Hispanic had higher survival
probability. Older age, longer education, and history of
major psychosis in patient’s primary relatives caused
lower survival rate. Marriage and female gender in-
creased NHFS; high value in Body mass index decreased
NHFS. All the above results were significant at 0.01 or
0.05 level. CONCLUSIONS: The study showed MMSE
was a strong predictor of patient survival and NHFS.
Further study should be conducted to explore the possi-
bility that MMSE score can be used as a clinical indicator
for treating AD patients. It is also interesting that, older
age doesn’t have significant impact on NHFS although it
is a strong predictor of survival. On the other hand, mar-
riage has a significant impact on NHFS, but not on sur-
vival.
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THE MIGRAINE IN FRANCE IN 2000: 
EPIDEMIOLOGICAL DATA
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OBJECTIVE: A French national epidemiological study
on migraine was presented 10 years ago at the Migraine
trust. It was the first study to cover an entire country
(HENRY P. et al.: Migraine prevalence in France. In New
advances in headache research: 2. Ed. Clifford Rose 1991
Smith Gordon—pp. : 11–14). This study has provided
also data on the burden of migraine in terms of its eco-
nomic and social impact. We would like today to update
the data. METHODS: 1486 persons, aged over 15 and
suffering from headaches were randomly selected from a
large representative sample of the French population.
They were asked to complete a questionnaire, which al-
lowed discriminating sufferers of migraine according to
IHS criteria. RESULTS: Among the 1486 headache suf-
ferers, we find 880 migrainous people (1-1, 1-2 and 1-7
IHS criteria), 454 without migrainous headache and 152
with chronic daily headache. If we compare the results of
the certain migraine group (1-1 and 1-2 IHS) we find that
they are identical (8,1% (1989) versus 8,2% (1999)).
However, if we include the migrainous disorder group
fulfilling all criteria but one (1-7 IHS), the prevalence rate
for migraine headache in France between 1989 and 1999
seems to show a clear increase, rising from 12,1% to
17,3% because of less restrictive criteria than those ap-
plied ten years ago. Regarding the prevalence in general
population for chronic daily headache the rate is around
3% with 1,8% for men and 3,9% for women in 1999.
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DIFFERENCES IN HEALTH-RELATED QUALITY 
OF LIFE BETWEEN MIGRAINEURS WITH AND 
WITHOUT PROPHYLACTIC MEDICATION USE
Girts TK, Lofland JH, O’Connor JP
Thomas Jefferson University, Philadelphia, PA, USA
In a previous study, sumatriptan therapy was associated
with improvements in Health Related Quality of Life
(HRQoL). Using the same population, the present study
explores additional changes in HRQoL between patients
who did and did not receive migraine prophylaxis medi-
cation. OBJECTIVES: To compare the difference in
HRQoL of migraineurs who did and did not receive mi-
graine prophylactic medication. METHODS: A retro-
spective database analysis was conducted using phar-
macy claims and HRQoL data. Study patients were from
a managed care organization, were diagnosed with mi-
graine, and were initiated on sumatriptan (baseline). The
SF-36 and Migraine-Specific Quality of Life Question-
naire-Version 1.0 (MSQ) surveys were administered at
baseline, 3 and 6 months after initiation of sumatriptan.
Patients were identified for the prophylaxis group if they
received any medication from a previously developed list
of possible migraine prophylaxis medications: 1) within
30 days prior to baseline and 2) at least 4 out of the 6
months after baseline. A two-way repeated measures
ANOVA was performed comparing differences in HRQoL
between the groups from baseline to 6 months. RESULTS:
Of 178 patients, 40 were in the prophylaxis group and
138 in the non-prophylaxis group. Statistically significant
increases were found in the MSQ Role Function-Restric-
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tive, and the SF-36 Role-Physical, Bodily Pain domains in
the non-prophylaxis group compared with the prophy-
laxis group (p-value 0.05). A statistically significant in-
crease was found in the SF-36 Physical Functioning
domain in the prophylaxis group compared with the non-
prophylaxis group (p-value 0.05). CONCLUSION: Al-
though sumatriptan has been shown to improve HRQoL
of migraineurs, concurrent use of prophylaxis medication
for migraineurs shows mixed results of any additional
benefit in HRQoL.
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DELAYS IN NURSING HOME PLACEMENT FOR 
PATIENTS WITH ALZHEIMER’S DISEASE 
ASSOCIATED WITH TREATMENT WITH 
DONEPEZIL MAY HAVE HEALTH CARE
COST-SAVING IMPLICATIONS
Provenzano G1, Duttagupta S2, McRae T2, Mastey V2, Ellis B1, 
Ieni J3
1Battelle Centers for Public Health Research and Evaluation, 
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OBJECTIVES: Donepezil, an anti-dementia drug, has
been associated with delays in nursing home placement
(NHP) for patients with Alzheimer’s disease (AD). This
analysis explores the health care cost-saving implications
of such treatment. METHODS: Information on the dates
and reasons for NHP was obtained through follow-up in-
terviews with caregivers and chart reviews of 763 AD pa-
tients who participated in three randomized, double-blind,
placebo-controlled clinical trials and two subsequent open-
label studies of donepezil. Patients were categorized ac-
cording to their experiences in utilizing donepezil during
the clinical trials and extension studies. Cox proportional
hazards models (adjusted for age, gender, baseline Mini-
Mental Status Examination scores, caregiver status and
post clinical study use of cholinesterase inhibitors) were
used to estimate adjusted survival functions from which
median times to NHP were estimated for each donepezil
use category. Analyses of the relationship between done-
pezil use and time to NHP were completed for both first
dementia-related placement (data reported here) and for
permanent placement (data similar). Standard nursing
home cost data were applied to these results. RESULTS:
For the least exposure group (dose 5 mg/day and/or
used drug for less than 8 weeks total; n  95), the me-
dian time to first dementia-related NHP was 43 months.
Compared with this group, patients who received at least
5 mg/day of donepezil for 8 weeks or more had a signifi-
cantly (p  0.05) longer time to first dementia-related
NHP. For patients who received donepezil for at least 36
weeks (12 weeks of double blind and 24 weeks of open-
label treatment, for example), the median time was 73
months to first dementia-related NHP (RR  0.458, p 
0.01). CONCLUSIONS: Because nursing home care has
been reported as the principal cost driver in the care of
AD patients, these delays to the time of entry into a nurs-
ing home associated with donepezil treatment may have
important health care cost-saving implications.
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A PROGNOSTIC MODEL TO PREDICT
QUALITY OF LIFE CHANCES AFTER 
SUBARACHNOID HEMORRHAGE
Toth K1, Szende A2, Contreraz M1, Machovich A1, Futo J1, 
Nyari I1
1National Institute of Neurosurgery, Budapest, Hungary; 
2AstraZeneca, Torokbalint, Hungary
OBJECTIVES: Traditionally, mainly survival chances are
considered at clinical decisions before major operations.
This study looked at the potential ability of the most
commonly used pre-operation estimators to predict health
related quality of life of subarachnoid hemorrhage (SAH)
patients one year after surgery. METHODS: 173 patients
underwent intracranial aneurysm surgery within 72
hours after SAH at the National Institute of Neurosur-
gery in 1998 and1999. Before surgery health status as-
sessment included Hunt-Hess (HH) grade as a measure of
neurological status, ASA physical status score, and CT
examination that determines the presence of intracerebral
hemorrhage (ICH) and Fisher scale. 12 months after the
surgery, patients were interviewed either by phone or
post by using the EQ-5D generic quality of life question-
naire. The relationship between the pre-operation health
status/risk estimators and one-year QoL values was ex-
amined by differences in mean EQ-5Dindex values and
by developing a regression model. F-statistics and stu-
dent-t tests have been used to test statistical significance.
RESULTS: Patients with ICH had lower EQ-5D index
values (0.32 vs. 0.70, p  0.001). Patients with Fisher
scores 3 had lower QoL than those with scores below
(0.35 vs. 0.68, p  0.001). HH grade 3 lead to lower
QoL values (0.05 vs. 0.66, p  0.001). Patients with ASA
scores 2 had also significantly lower QoL (0.18 vs.
0.66, p  0.001). Due to similar meaning and high corre-
lation between ICH status and Fisher score, Fisher score
was dropped from the prognostic model. Regression
model included: EQ-5Dindex  1.04 V 0.38fx(ASA 
2) V 0.24fxICH V 0.30fx(HH  3) V 0.006fxAGE.
The overall model showed an R2  0.412, and p-value
0.001. P-values for individual coefficients were 0.0001,
0.0001, 0.0001, 0.002, and 0.012, respectively. CON-
CLUSIONS: Pre-operation health status/risk assessment
can predict future quality of life to an important extent.
It is argued that QoL chances should also be considered
in addition to survival chances. These results can be use-
ful in sub-group analyses in modeling studies.
